Listen
Reason for request
Reassessment of inclusion on the list of drugs reimbursed by National Health Insurance and of the improvement in actual benefit of beta interferons and glatiramer acetate indicated in multiple sclerosis.
-
Clinical Benefit
| Substantial |
The actual benefit of this medicinal product remains substantial. |
Clinical Added Value
| moderate |
In view of the absence of demonstrated long-term efficacy against disability provided by the medicinal product BETAFERON, the improvement in actual benefit is level III in the treatment of patients with multiple sclerosis. |
Documents
Contact Us
Évaluation des médicaments
